Carcinoid Syndrome - 25 Studies Found

Withdrawn : Study of Panitumumab in the Treatment of Carcinoid Syndrome
: Carcinoid Syndrome
: 2010-07-28
: Drug: Panitumumab Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of stu
Completed : Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
: Symptoms of Carcinoid Syndrome
: 2010-04-12
:
  • Drug: Low Dose LX1606 - Day 1 (start)

Terminated : Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
: Malignant Carcinoid Syndrome
: 2004-09-22
:
  • Drug: lanreotide Autogel (somatostatin analogue)
Completed : Effects of Serotonin Excess on Bone in Carcinoid Syndrome
: Carcinoid Syndrome
: 2011-08-26
Completed : Telotristat Etiprate for Carcinoid Syndrome Therapy
: Carcinoid Syndrome
: 2014-02-12
:
  • Drug: Telotristat etiprate tablets (250 mg)

Terminated : Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
: Carcinoid Syndrome
: 2009-04-20
: Drug: Octreotide short acting octreotide
Completed : An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
: Carcinoid Syndrome
: 2008-10-15
:
  • Drug: Lanreotide deep s.c. inj
Terminated : Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
: Carcinoid Syndrome
: 2009-11-24
: Drug: BIM 23A760 BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection
Completed : TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
: Carcinoid Syndrome
: 2012-08-30
:
  • Drug: Telotristat etiprate tablets (250 mg)

Active, not recruiting : Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
: Carcinoid Syndrome
: 2013-12-31
: Drug: Telotristat etiprate tablets (250 mg) Other Name: LX1606
Next >>>